Related Experiment Video

Updated: May 8, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Mild cognitive impairment in Parkinson's disease: a review of current concepts

Natalie C Palavra1, Sharon L Naismith, Simon J G Lewis

  • 1Parkinson's Disease Research Clinic, Brain & Mind Research Institute, University of Sydney, 94 Mallett Street, Camperdown, NSW 2050, Australia.

Neurology Research International
|August 13, 2013
PubMed

Insights

Mild Cognitive Impairment in Parkinson's Disease (PD-MCI) is common and linked to dementia. Early detection and new treatments for PD-MCI are crucial for managing cognitive decline in Parkinson's patients.

Area of Science:

  • Neurology
  • Neuroscience
  • Cognitive Science

Background:

  • Mild Cognitive Impairment in Parkinson's Disease (PD-MCI) is a prevalent condition.
  • PD-MCI is associated with an increased risk of progressing to dementia.
  • Recent advancements have led to new diagnostic criteria for PD-MCI.

Purpose of the Study:

  • To review current definitions and diagnostic criteria for PD-MCI.
  • To explore screening tools, cognitive patterns, and predictors of cognitive decline in PD-MCI.
  • To consider emerging biomarkers and novel therapeutic interventions for PD-MCI.

Main Methods:

  • Literature review of current definitions and diagnostic criteria for PD-MCI.
  • Analysis of screening tools and observed cognitive deficits.
  • Examination of predictors for cognitive decline and progression to Parkinson's Disease Dementia.
  • Review of emerging biomarkers and potential treatment options.

Main Results:

  • PD-MCI is a significant clinical entity with implications for disease progression.
  • Specific cognitive deficits are characteristic of PD-MCI.
  • Predictors of cognitive decline and transition to dementia have been identified.
  • Biomarkers and therapeutic targets are under investigation.

Conclusions:

  • Early identification and accurate classification of PD-MCI are essential.
  • Understanding PD-MCI facilitates the development of targeted interventions.
  • Further research into biomarkers and treatments holds promise for managing PD-MCI and preventing dementia.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...